346 related articles for article (PubMed ID: 34445605)
1. Clearance of the SARS-CoV-2 Virus in an Immunocompromised Patient Mediated by Convalescent Plasma without B-Cell Recovery.
Basheer M; Saad E; Laskar O; Schuster O; Rechnitzer H; Zisman-Rozen S; Azoulay D; Assy N
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445605
[TBL] [Abstract][Full Text] [Related]
2. Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery.
Zimmerli A; Monti M; Fenwick C; Eckerle I; Beigelman-Aubry C; Pellaton C; Jaton K; Dumas D; Stamm GM; Infanti L; Andreu-Ullrich H; Germann D; Mean M; Vollenweider P; Stadelmann R; Prella M; Comte D; Guery B; Gachoud D; Rufer N
Front Immunol; 2021; 12():613502. PubMed ID: 33968017
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?
Rnjak D; Ravlić S; Šola AM; Halassy B; Šemnički J; Šuperba M; Hećimović A; Kurolt IC; Kurtović T; Mačak Šafranko Ž; Polančec D; Bendelja K; Mušlin T; Jukić I; Vuk T; Zenić L; Artuković M
Transfus Clin Biol; 2021 Aug; 28(3):264-270. PubMed ID: 33901641
[TBL] [Abstract][Full Text] [Related]
4. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
[TBL] [Abstract][Full Text] [Related]
5. Dramatic Response to Convalescent Hyperimmune Plasma in Association With an Extended Course of Remdesivir in 4 B Cell-Depleted Non-Hodgkin Lymphoma Patients With SARS-Cov-2 Pneumonia After Rituximab Therapy.
Furlan A; Forner G; Cipriani L; Vian E; Rigoli R; Gherlinzoni F; Scotton P
Clin Lymphoma Myeloma Leuk; 2021 Sep; 21(9):e731-e735. PubMed ID: 34217677
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 evolution during treatment of chronic infection.
Kemp SA; Collier DA; Datir RP; Ferreira IATM; Gayed S; Jahun A; Hosmillo M; Rees-Spear C; Mlcochova P; Lumb IU; Roberts DJ; Chandra A; Temperton N; ; ; Sharrocks K; Blane E; Modis Y; Leigh KE; Briggs JAG; van Gils MJ; Smith KGC; Bradley JR; Smith C; Doffinger R; Ceron-Gutierrez L; Barcenas-Morales G; Pollock DD; Goldstein RA; Smielewska A; Skittrall JP; Gouliouris T; Goodfellow IG; Gkrania-Klotsas E; Illingworth CJR; McCoy LE; Gupta RK
Nature; 2021 Apr; 592(7853):277-282. PubMed ID: 33545711
[TBL] [Abstract][Full Text] [Related]
7. Emerging RNA-Dependent RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With Protracted Coronavirus Disease 2019.
Martinot M; Jary A; Fafi-Kremer S; Leducq V; Delagreverie H; Garnier M; Pacanowski J; Mékinian A; Pirenne F; Tiberghien P; Calvez V; Humbrecht C; Marcelin AG; Lacombe K
Clin Infect Dis; 2021 Oct; 73(7):e1762-e1765. PubMed ID: 32986807
[TBL] [Abstract][Full Text] [Related]
8. Severe Acute Respiratory Syndrome Coronavirus-2 Pneumonia in a Newborn Treated With Remdesivir and Coronavirus Disease 2019 Convalescent Plasma.
Hopwood AJ; Jordan-Villegas A; Gutierrez LD; Cowart MC; Vega-Montalvo W; Cheung WL; McMahan MJ; Gomez MR; Laham FR
J Pediatric Infect Dis Soc; 2021 May; 10(5):691-694. PubMed ID: 33306130
[TBL] [Abstract][Full Text] [Related]
9. A Novel In-Cell ELISA Assay Allows Rapid and Automated Quantification of SARS-CoV-2 to Analyze Neutralizing Antibodies and Antiviral Compounds.
Schöler L; Le-Trilling VTK; Eilbrecht M; Mennerich D; Anastasiou OE; Krawczyk A; Herrmann A; Dittmer U; Trilling M
Front Immunol; 2020; 11():573526. PubMed ID: 33162987
[TBL] [Abstract][Full Text] [Related]
10. Regen-COV-2 Antibody Cocktail Mediated Clearance of SARS-COV-2 in an Immunocompromised Patient.
Basheer M; Saad E; Milhem F; Budman D; Assy N
Isr Med Assoc J; 2022 Nov; 24(11):695-696. PubMed ID: 36436032
[TBL] [Abstract][Full Text] [Related]
11. Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis.
Curtò D; Tomatis F; Gastoldi S; Galbusera M; Noris M; Raimondi F; Lorini FL; Falanga A; Marchetti M; Remuzzi G; Ruggenenti P
Front Immunol; 2021; 12():711915. PubMed ID: 34276706
[TBL] [Abstract][Full Text] [Related]
12. Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products.
Kenig A; Ishay Y; Kharouf F; Rubin L
Clin Immunol; 2021 Jun; 227():108723. PubMed ID: 33838340
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity.
Kremer AE; Kremer AN; Willam C; Völkl S; Verhagen J; Achenbach S; van der Meijden ED; Lang V; Aigner M; Maier C; Tenbusch M; Korn K; Lutzny-Geier G; Spoerl S; Strauß R; Vetter M; Überla K; Neurath MF; Mackensen A; Schiffer M; Hackstein H
Eur J Immunol; 2021 Oct; 51(10):2478-2484. PubMed ID: 34350584
[TBL] [Abstract][Full Text] [Related]
14. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
[TBL] [Abstract][Full Text] [Related]
15. Sustained Response After Remdesivir and Convalescent Plasma Therapy in a B-Cell-Depleted Patient With Protracted Coronavirus Disease 2019 (COVID-19).
Malsy J; Veletzky L; Heide J; Hennigs A; Gil-Ibanez I; Stein A; Lütgehetmann M; Rosien U; Jasper D; Peine S; Hiller J; Haag F; Schmiedel S; Huber S; Jordan S; Addo MM; Schulze Zur Wiesch J
Clin Infect Dis; 2021 Dec; 73(11):e4020-e4024. PubMed ID: 33103195
[TBL] [Abstract][Full Text] [Related]
16. Treatment of chronic or relapsing COVID-19 in immunodeficiency.
Brown LK; Moran E; Goodman A; Baxendale H; Bermingham W; Buckland M; AbdulKhaliq I; Jarvis H; Hunter M; Karanam S; Patel A; Jenkins M; Robbins A; Khan S; Simpson T; Jolles S; Underwood J; Savic S; Richter A; Shields A; Brown M; Lowe DM
J Allergy Clin Immunol; 2022 Feb; 149(2):557-561.e1. PubMed ID: 34780850
[TBL] [Abstract][Full Text] [Related]
17. COVID-19: Antiviral Agents, Antibody Development and Traditional Chinese Medicine.
Guan W; Lan W; Zhang J; Zhao S; Ou J; Wu X; Yan Y; Wu J; Zhang Q
Virol Sin; 2020 Dec; 35(6):685-698. PubMed ID: 32997322
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma.
Lindemann M; Krawczyk A; Dolff S; Konik M; Rohn H; Platte M; Thümmler L; Schwarzkopf S; Schipper L; Bormann M; van de Sand L; Breyer M; Klump H; Knop D; Lenz V; Temme C; Dittmer U; Horn PA; Witzke O
J Med Virol; 2021 May; 93(5):3047-3054. PubMed ID: 33527424
[TBL] [Abstract][Full Text] [Related]
19. Convalescent plasma and remdesivir for protracted COVID-19 in a patient with chronic lymphocytic leukaemia: a case report of late relapse after rapid initial response.
Schenker C; Hirzel C; Walti LN; Zeerleder SS; Andres M; Ramette A; Barbani MT; Suter-Riniker F; Holbro A; Tritschler T
Br J Haematol; 2022 Feb; 196(3):e27-e29. PubMed ID: 34458995
[No Abstract] [Full Text] [Related]
20. Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population.
Yi Z; Ling Y; Zhang X; Chen J; Hu K; Wang Y; Song W; Ying T; Zhang R; Lu H; Yuan Z
Emerg Microbes Infect; 2020 Dec; 9(1):1988-1996. PubMed ID: 32844713
[No Abstract] [Full Text] [Related]
[Next] [New Search]
